Tranexamic Acid in Treatment of Facial Erythema

NCT05897918 | Completed

• 1 other identifier: MSc/AZAST/DVA021/18/215/1/2023
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Our aim is to evaluate the efficacy of 10% topical tranexamic acid with microneedling in treatment of facial erythema

Conditions

Patient With Facial Erythema

Outcome Measures

Primary Outcomes (1)

• change in facial erythema

  method of measurement by clinician erythema assessment score Description Score Clear skin with no signs of erythema 0 Almost clear; slight redness 1 Mild erythema, definite redness 2 Moderate erythema; marked redness 3 Severe erythema; fiery redness 4 by clinician erythema assesment score

  after 6 week of end point

Study Arms (1)

single group

OTHER

Drug: Tranexamic Acid 500 MG

Interventions

Tranexamic Acid 500 MG DRUG

Each patient received treatment on both sides of the face, one side treated by micro needling with 10% topical tranexamic acid, and othert side treated by 10% topical tranexamic acid alone every 2 weeks for 3 sessions

single group

Eligibility Criteria

• Age: 20 Years - 50 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Female Patients clinical diagnosis with persistent facial erythema and telangiectasia. Co-operative patient and patients willing for the procedure

You may not qualify if:

• active infection at the local site or recurrent herpes. bleeding disorders or anticoagulant medications scar and keloid formation. unrealistic expectations. Pregnant or lactating women

Sponsors & Collaborators

• Al-Azhar University: lead

Study Sites (1)

Azhar University

Asyut, Egypt

Location

Related Links

• Red face revisited: Flushing 2014.
• red face': not always rosacea 2016.
• The Great Mimickers of Rosacea 2014.

MeSH Terms

Interventions

Tranexamic Acid

Intervention Hierarchy (Ancestors)

Cyclohexanecarboxylic Acids; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: qena

Study Record Dates

• First Submitted: June 1, 2023
• First Posted: June 9, 2023
• Study Start: August 1, 2020
• Primary Completion: August 1, 2022
• Study Completion: August 30, 2022
• Last Updated: June 12, 2023

Record last verified: 2023-06

Locations

EG (1)